This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.
Kazi Kutubuddin,
Heena Shaikh,
- Professor, BMIT, Solapur, Maharashtra, India
- Professor, BMIT, Solapur, Maharashtra, India
Abstract
Antibiotic resistance (AR) represents one of the most critical existential threats to global public health, rapidly eroding the efficacy of established antimicrobial therapies and portending a return to the pre-antibiotic era. This analysis explores the intricate molecular landscape defining this crisis, focusing specifically on the primary mechanisms of action (MoA) utilized by major antibiotic classes—including cell wall inhibitors, protein synthesis inhibitors, and nucleic acid synthesis inhibitors—and the corresponding, diverse mechanisms of resistance (MoR) evolved by pathogenic bacteria. The core MoR identified involve: (1) Enzymatic Inactivation, notably achieved through the widespread proliferation of $beta$-lactamases; (2) Target Site Modification, structurally altering critical binding sites (e.g., PBP2a in MRSA); and (3) Reduced Intracellular Concentration, mediated by enhanced efflux pump activity or decreased membrane permeability. These MoR are often encoded on mobile genetic elements, facilitating rapid horizontal transfer across species. Understanding the precise interplay between MoA and MoR is paramount, as current drug discovery efforts struggle to keep pace with the velocity of bacterial adaptation. The imperative is clear: a radical paradigm shift toward non- traditional therapeutics and resistance-breaking strategies is urgently required to preserve the foundation of modern medicine.
Keywords: Antibiotics, Antibiotic resistance, Enzymatic inactivation, Target site modification, intercellular concentration
Kazi Kutubuddin, Heena Shaikh. A study on Antibiotic Resistance: An Analysis of Molecular Mechanisms and Therapeutic Implications. International Journal of Antibiotics. 2026; 03(01):-.
Kazi Kutubuddin, Heena Shaikh. A study on Antibiotic Resistance: An Analysis of Molecular Mechanisms and Therapeutic Implications. International Journal of Antibiotics. 2026; 03(01):-. Available from: https://journals.stmjournals.com/ijab/article=2026/view=236724
References
[1]. Habboush Y, Guzman N. Antibiotic Resistance. 2022 Jun 23. StatPearls [Internet].
Treasure Island (FL): StatPearls Publishing. 2023.
[2]. Uddin TM, Chakraborty AJ, Khusro A, Zidan BR, Mitra S, Emran TB, Dhama K, Ripon
MK, Gajdács M, Sahibzada MU, Hossain MJ. Antibiotic resistance in microbes: History,
mechanisms, therapeutic strategies and future prospects. Journal of infection and public
health. 2021 Dec 1;14(12):1750-66.
[3]. Czaplewski L, Bax R, Clokie M, Dawson M, Fairhead H, Fischetti VA, Foster S,
Gilmore BF, Hancock RE, Harper D, Henderson IR. Alternatives to antibiotics—a
pipeline portfolio review. The Lancet infectious diseases. 2016 Feb 1;16(2):239-51.
[4]. Czaplewski L, Bax R, Clokie M, Dawson M, Fairhead H, Fischetti VA, Foster S,
Gilmore BF, Hancock RE, Harper D, Henderson IR. Alternatives to antibiotics—a
pipeline portfolio review. The Lancet infectious diseases. 2016 Feb 1;16(2):239-51.
[5]. Gould K. Antibiotics: from prehistory to the present day. Journal of Antimicrobial
Chemotherapy. 2016 Mar 1;71(3):572-5.
[6]. Nicolaou KC, Rigol S. A brief history of antibiotics and select advances in their
synthesis. The Journal of antibiotics. 2018 Feb;71(2):153-84.
[7]. Pallasch TJ. Antibiotics: past, present, and future. CDA journal. 1986 May 1;14(5):65-8.
[8]. Sköld O. Sulfonamide resistance: mechanisms and trends. Drug resistance updates. 2000
Jun 1;3(3):155-60.
[9]. Tan SY, Tatsumura Y. Alexander Fleming (1881–1955): discoverer of penicillin.
Singapore medical journal. 2015 Jul;56(7):366.
[10]. World Health Organization. Antibacterial agents in clinical development: an
analysis of the antibacterial clinical development pipeline, including tuberculosis. World
Health Organization; 2017.
[11]. Frieri M, Kumar K, Boutin A. Antibiotic resistance. Journal of infection and public
health. 2017 Jul 1;10(4):369-78.
[12]. Liyakat KK, Khadake SB, Chounde AB, Suryagan AA, HM M, Khadatare MR. AI-
Driven-IoT (AIIoT) Based Decision Making System for High-Blood Pressure Patient
Healthcare Monitoring. In2024 International Conference on Sustainable Communication
Networks and Application (ICSCNA) 2024 Dec 11 (pp. 96-102). IEEE.
[13]. Liyakat KK, Khadake SB, More PS, Shinde RJ, Kondubhairi KP, Kamble SS. AI-
Driven IoT based Decision Making for Hepatitis Diseases Patient’s Healthcare
Monitoring: KSK Approach for Hepatitis Patient Monitoring. In2025 7th International
Conference on Intelligent Sustainable Systems (ICISS) 2025 Mar 12 (pp. 256-263).
IEEE.
[14]. Liyakat KK, Khadake SB, Galani K, Patil KB, Dhavale A, Sarik SD. AI-Powered-IoT
(AIIoT) based Bridge Health Monitoring using Sensor Data for Smart City Management-
A KSK Approach. In2025 7th International Conference on Intelligent Sustainable
Systems (ICISS) 2025 Mar 12 (pp. 296-305). IEEE.
[15]. Liyakat KK, Khadake SB, Ingale BR, DD D, Sudake SS, Awatade MM. Kidney
Diseases Patient Healthcare Monitoring using AI-Driven-IoT (AIIoT)-An KSK1
Approach. In2025 7th International Conference on Intelligent Sustainable Systems
(ICISS) 2025 Mar 12 (pp. 264-272). IEEE.
[16]. [Liyakat KK, Khadake SB, Chounde AB, Suryagan AA, HM M, Khadatare MR. AI-
Driven-IoT (AIIoT) Based Decision Making System for High-Blood Pressure Patient
Healthcare Monitoring. In2024 International Conference on Sustainable Communication
Networks and Application (ICSCNA) 2024 Dec 11 (pp. 96-102). IEEE.
International Journal of Antibiotics
| Volume | 03 |
| 01 | |
| Received | 28/10/2025 |
| Accepted | 14/11/2025 |
| Published | 20/01/2026 |
| Publication Time | 84 Days |
Login
PlumX Metrics